Prognostic impact of phosphorylated HER-2 in HER-2 + primary breast cancer

Oncologist

Volumn 16, Issue 7, 2011, Pages 956-965

  Hayashi, Naoki ^a,b,c   Iwamoto, Takayuki ^a,d   Gonzalez Angulo, Ana M ^a   Ferrer Lozano, Jaime ^e   Lluch, Ana ^e   Niikura, Naoki ^a   Bartholomeusz, Chandra ^a   Nakamura, Seigo ^b,c   Hortobagyi, Gabriel N ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Breast cancer; HER 2; Metastases; Phosphorylation; Reverse phase protein array

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; TYROSINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 79960875009     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0409     Document Type: Article

References (43)

1. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-948.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
3. ® (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001;37(suppl 1):S25-S29.
4. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients withHER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
5. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and pacli-taxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783-792.
7. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
8. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17: 2639-2648.
9. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
10. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402.
11. Fujita T, Doihara H, Kawasaki K et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006;94:247-252.
12. Fujita T, Doihara H, Washio K et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006;17:455-462.
13. Lu CH, Wyszomierski SL, Tseng LM et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-5888.
14. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-3158.
15. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance inpatients. Cancer Cell 2004;6:117-127.
16. Nagy P, Friedländer E, Tanner M et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-482.
17. Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8:215.
18. Nahta R, Yu D, Hung MC et al. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-280.
19. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-5847.
20. Cicenas J, Urban P, Kng W et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006;42:636-645.
21. Dankort D, Jeyabalan N, Jones N et al. Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins. J Biol Chem 2001;276:38921-38928.
22. DiGiovanna MP, Carter D, Flynn SD et al. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 1996;74:802-806.
23. Frogne T, Laenkholm AV, Lyng MB et al. Determination of HER2 phos-phorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009;11:R11.
24. Giuliani R, Durbecq V, Di Leo A et al. Phosphorylated HER-2 tyrosine ki-nase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007;43:725-735.
25. Hudelist G, Köstler WJ, Attems J et al. Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 2003;89:983-991.
26. Hudelist G, Köstler WJ, Czerwenka K et al. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 2006;118:1126-1134.
27. Modi S, DiGiovanna MP, Lu Z et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for met-astatic breast cancer. Cancer Invest 2005;23:483-487.
28. Singer CF, Gschwantler-Kaulich D, Fink-Retter A et al. HER2 overexpres-sion and activation, and tamoxifen efficacy in receptor-positive early breast cancer. J Cancer Res Clin Oncol 2009;135:807-813.
29. Thor AD, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A studyof incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-3239.
30. DiGiovanna MP, Stern DF, Edgerton SM et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23:1152-1160.
31. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472-2478.
32. Hennessy BT, Lu Y, Poradosu E et al. Pharmacodynamic markers of peri-fosine efficacy. Clin Cancer Res 2007;13:7421-7431.
33. Hu J, He X, Baggerly KA et al. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-1994.
34. Liang J, Shao SH, Xu ZX et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-224.
35. Tibes R, Qiu Y, Lu Y et al. Reverse phase protein array: Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-2521.
36. DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995;55:1946-1955.
37. Harder KW, Owen P, Wong LK et al. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta (HPTP beta) using synthetic phosphopeptides. Biochem J 1994;298:395-401.
38. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
39. Akiyama T, Matsuda S, Namba Y et al. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 1991;11:833-842.
40. Berezov A, Greene MI. Towards comprehensive characterization of HER2 overexpression. Mol Syst Biol 2006;2:55.
41. Telesco SE, Radhakrishnan R. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: A molecular dynamics study. Biophys J 2009;96:2321-2334.
42. Ramaswamy A, Lin E, Chen I et al. Application of protein lysate microar-rays to molecular marker verification and quantification. Proteome Sci 2005;3:9.
43. Hennessy BT, Lu Y, Gonzalez-Angulo AM et al. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Pro-teomics 2010;6:129-151.